INTRODUCTION: The occurrence of lower prostate-specific antigen (PSA) levels in overweight White and African American men has been studied, but there is no data regarding Hispanics, which have a higher mortality rate from Prostate Cancer (PCa) than Whites. The objective of this study was to investigate if being overweight could affect both the sensitivity of the PSA as a diagnostic tool and the progression of PCa in this group. METHODS: Retrospective study of records from 400 patients that underwent testing for PCa during 2005 and 400 patients under treatment for PCa from 2003-2005 at the urology clinics of the Veterans Administration Caribbean Healthcare System. Accrued data included body mass index (BMI), age, PSA levels, biopsy results, and cancer status after treatment. RESULTS: In men, with normal age adjusted PSA levels, overweight and obese men had 35.38% and 38.13%, respectively, positive biopsies while men with normal BMI had 26.15%. In addition, 73.84% of overweight men over 61 years old with normal PSA were positive for prostate cancer. There is a statistically significant decrease in PSA sensitivity from 71.7 (95% CI: 58.6-82.5) in men with normal BMI to 55.4 (95% CI: 41.5-68.7) in obese men (P = .015). In multivariate analysis, patients with a BMI over 25 kg/m2 had a 2.63 (CI 95%: 1.23-5.64) fold higher risk of metastases than those with normal BMI. CONCLUSIONS: in overweight Hispanic men the PSA level is a less sensitive marker for PCa and those individuals with higher BMI have higher prevalence of metastatic disease.
INTRODUCTION: The occurrence of lower prostate-specific antigen (PSA) levels in overweight White and African American men has been studied, but there is no data regarding Hispanics, which have a higher mortality rate from Prostate Cancer (PCa) than Whites. The objective of this study was to investigate if being overweight could affect both the sensitivity of the PSA as a diagnostic tool and the progression of PCa in this group. METHODS: Retrospective study of records from 400 patients that underwent testing for PCa during 2005 and 400 patients under treatment for PCa from 2003-2005 at the urology clinics of the Veterans Administration Caribbean Healthcare System. Accrued data included body mass index (BMI), age, PSA levels, biopsy results, and cancer status after treatment. RESULTS: In men, with normal age adjusted PSA levels, overweight and obesemen had 35.38% and 38.13%, respectively, positive biopsies while men with normal BMI had 26.15%. In addition, 73.84% of overweight men over 61 years old with normal PSA were positive for prostate cancer. There is a statistically significant decrease in PSA sensitivity from 71.7 (95% CI: 58.6-82.5) in men with normal BMI to 55.4 (95% CI: 41.5-68.7) in obesemen (P = .015). In multivariate analysis, patients with a BMI over 25 kg/m2 had a 2.63 (CI 95%: 1.23-5.64) fold higher risk of metastases than those with normal BMI. CONCLUSIONS: in overweight Hispanic men the PSA level is a less sensitive marker for PCa and those individuals with higher BMI have higher prevalence of metastatic disease.
Authors: Carmen Rodriguez; Stephen J Freedland; Anusila Deka; Eric J Jacobs; Marjorie L McCullough; Alpa V Patel; Michael J Thun; Eugenia E Calle Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-12-19 Impact factor: 4.254
Authors: S O Andersson; A Wolk; R Bergström; H O Adami; G Engholm; A Englund; O Nyrén Journal: J Natl Cancer Inst Date: 1997-03-05 Impact factor: 13.506
Authors: Tung H Ngo; R James Barnard; Christopher N Tymchuk; Pinchas Cohen; William J Aronson Journal: Cancer Causes Control Date: 2002-12 Impact factor: 2.506
Authors: Constanza M López Fontana; Gabriela M Recalde Rincón; Diego Messina Lombino; Ana L Uvilla Recupero; Rafael F Pérez Elizalde; José D López Laur Journal: Actas Urol Esp Date: 2009 Jul-Aug Impact factor: 0.994
Authors: Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun Journal: CA Cancer J Clin Date: 2003 Jan-Feb Impact factor: 508.702
Authors: Velda J González-Mercado; Jean Lim; Lawrence Berk; Mary Esele; Carmen S Rodríguez; Gerardo Colón-Otero Journal: Curr Probl Cancer Date: 2020-01-27 Impact factor: 3.187
Authors: June M Chan; Stacey A Kenfield; Rebecca E Graff; Crystal S Langlais; Erin L Van Blarigan; Claire H Pernar; Meir J Stampfer; Edward L Giovannucci; Lorelei A Mucci Journal: Br J Cancer Date: 2022-08-26 Impact factor: 9.075
Authors: Jeannette L Salgado-Montilla; Jorge L Rodríguez-Cabán; Jonathan Sánchez-García; Ricardo Sánchez-Ortiz; Margarita Irizarry-Ramírez Journal: Arch Cancer Res Date: 2017-08-22
Authors: Crystal S Langlais; Rebecca E Graff; Erin L Van Blarigan; Nynikka R Palmer; Samuel L Washington; June M Chan; Stacey A Kenfield Journal: Curr Oncol Rep Date: 2021-03-10 Impact factor: 5.075